TuHURA BIOSCIENCES, INC./NV Net Income (Loss) Available to Common Stockholders, Basic
TuHURA BIOSCIENCES, INC./NV (HURA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$9.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$9.23M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$7.54M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$6.76M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$7.10M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for fiscal 2025 was -$30.06M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for fiscal 2024 was -$22.65M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for fiscal 2024 was -$8.50M.
- TuHURA BIOSCIENCES, INC./NV net income (loss) available to common stockholders, basic for fiscal 2023 was -$29.32M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.23M 10-Q · filed 2026-08-14 | -$16.76M 10-Q · filed 2026-08-14 | -$23.53M derived: sum of 3 quarters · filed 2026-08-14 | -$30.63M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$7.54M 10-Q · filed 2026-05-15 | -$14.30M derived: sum of 2 quarters · filed 2026-05-15 | -$21.41M derived: sum of 3 quarters · filed 2026-05-15 | -$30.93M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$6.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$13.87M derived: sum of 2 quarters · filed 2026-03-31 | -$23.39M derived: sum of 3 quarters · filed 2026-08-14 | -$30.06M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$7.10M 10-Q · filed 2025-11-14 | -$16.63M derived: sum of 2 quarters · filed 2026-08-14 | -$23.30M 10-Q · filed 2025-11-14 | -$29.29M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$9.53M 10-Q · filed 2026-08-14 | -$16.19M 10-Q · filed 2026-08-14 | -$22.19M derived: sum of 3 quarters · filed 2026-08-14 | -$28.73M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$6.67M 10-Q · filed 2026-05-15 | -$12.66M derived: sum of 2 quarters · filed 2026-05-15 | -$19.21M derived: sum of 3 quarters · filed 2026-05-15 | -$24.47M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$12.54M derived: sum of 2 quarters · filed 2026-03-31 | -$17.81M derived: sum of 3 quarters · filed 2026-03-31 | -$22.65M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$6.54M 10-Q · filed 2025-11-14 | -$2.18M 10-Q · filed 2024-11-14 | -$11.81M derived: sum of 2 quarters · filed 2025-11-14 | -$16.65M 10-Q · filed 2025-11-14 | -$17.68M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$5.27M 10-Q · filed 2025-08-14 | -$10.11M 10-Q · filed 2025-08-14 | -$11.13M derived: sum of 3 quarters · filed 2025-08-14 | -$8.50M 10-K · filed 2024-10-07 | ||||
| 2024-03-31 | -$4.84M 10-Q · filed 2025-05-15 | -$2.01M 10-Q · filed 2024-05-14 | -$5.87M derived: sum of 2 quarters · filed 2025-05-15 | -$6.17M 10-Q · filed 2024-05-14 | -$12.34M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$1.02M 10-Q · filed 2024-02-14 | -$4.16M 10-Q · filed 2024-02-14 | -$7.50M derived: sum of 3 quarters · filed 2024-11-14 | -$29.32M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$3.14M 10-Q · filed 2024-11-14 | -$6.47M derived: sum of 2 quarters · filed 2024-11-14 | -$9.74M derived: sum of 3 quarters · filed 2024-11-14 | -$13.20M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-07 | -$6.60M derived: sum of 2 quarters · filed 2024-10-07 | -$10.06M derived: sum of 3 quarters · filed 2024-10-07 | -$15.02M 10-K · filed 2024-10-07 | ||||
| 2023-03-31 | -$3.27M 10-Q · filed 2024-05-14 | -$6.72M derived: sum of 2 quarters · filed 2024-05-14 | -$11.68M 10-Q · filed 2024-05-14 | -$17.13M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$3.46M 10-Q · filed 2024-02-14 | -$8.42M 10-Q · filed 2024-02-14 | -$13.86M derived: sum of 3 quarters · filed 2024-02-14 | -$19.22M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-09-30 | -$4.96M 10-Q · filed 2023-11-13 | -$10.41M derived: sum of 2 quarters · filed 2023-11-13 | -$15.77M derived: sum of 3 quarters · filed 2023-11-13 | -$21.66M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-18 | -$10.81M derived: sum of 2 quarters · filed 2023-09-18 | -$16.70M derived: sum of 3 quarters · filed 2023-09-18 | -$25.13M 10-K · filed 2023-09-18 | ||||
| 2022-03-31 | -$5.36M 10-Q · filed 2023-05-11 | -$11.25M derived: sum of 2 quarters · filed 2023-05-11 | -$19.68M 10-Q · filed 2023-05-11 | -$26.42M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$5.89M 10-Q · filed 2023-02-14 | -$14.32M 10-Q · filed 2023-02-14 | -$21.06M derived: sum of 3 quarters · filed 2023-02-14 | -$27.70M derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-09-30 | -$8.43M 10-Q · filed 2022-11-09 | -$15.17M derived: sum of 2 quarters · filed 2022-11-09 | -$21.81M derived: sum of 3 quarters · filed 2022-11-09 | -$27.23M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$13.38M derived: sum of 2 quarters · filed 2022-09-27 | -$18.80M derived: sum of 3 quarters · filed 2022-09-27 | -$41.50M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | -$6.64M 10-Q · filed 2022-05-13 | -$12.06M derived: sum of 2 quarters · filed 2022-05-13 | -$34.77M 10-Q · filed 2022-05-13 | -$38.60M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | -$5.42M 10-Q · filed 2022-02-11 | -$28.13M 10-Q · filed 2022-02-11 | -$31.95M derived: sum of 3 quarters · filed 2022-02-11 | -$33.91M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-09-30 | -$22.71M 10-Q · filed 2021-11-15 | -$26.53M derived: sum of 2 quarters · filed 2021-11-15 | -$28.49M derived: sum of 3 quarters · filed 2021-11-15 | -$30.24M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | -$5.79M derived: sum of 2 quarters · filed 2021-09-28 | -$7.53M derived: sum of 3 quarters · filed 2021-09-28 | -$9.14M 10-K · filed 2021-09-28 | -$9.13M 10-K · filed 2020-09-18 | |||
| 2020-03-31 | -$1.96M 10-Q · filed 2021-05-13 | -$1.96M 10-Q · filed 2020-05-13 | -$3.71M derived: sum of 2 quarters · filed 2021-05-13 | -$5.32M 10-Q · filed 2021-05-13 | -$5.31M 10-Q · filed 2020-05-13 | -$7.90M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$1.75M 10-Q · filed 2021-02-12 | -$1.74M 10-Q · filed 2020-02-13 | -$3.35M 10-Q · filed 2021-02-12 | -$3.35M 10-Q · filed 2020-02-13 | -$5.94M derived: sum of 3 quarters · filed 2021-02-12 | -$7.63M derived: sum of 4 quarters · filed 2021-02-12 | ||
| 2019-09-30 | -$1.61M 10-Q · filed 2020-11-12 | -$1.61M 10-Q · filed 2019-11-13 | -$4.20M derived: sum of 2 quarters · filed 2020-11-12 | -$5.88M derived: sum of 3 quarters · filed 2020-11-12 | -$7.71M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-18 | -$4.27M derived: sum of 2 quarters · filed 2020-09-18 | -$6.10M derived: sum of 3 quarters · filed 2020-09-18 | -$8.13M 10-K · filed 2020-09-18 | $8.13M 10-K · filed 2019-09-09 | |||
| 2019-03-31 | -$1.69M 10-Q · filed 2020-05-13 | -$3.51M derived: sum of 2 quarters · filed 2020-05-13 | -$5.54M 10-Q · filed 2020-05-13 | $14.68M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | -$1.83M 10-Q · filed 2020-02-13 | -$3.85M 10-Q · filed 2020-02-13 | $16.36M derived: sum of 3 quarters · filed 2020-02-13 | $13.38M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-09-30 | -$2.03M 10-Q · filed 2019-11-13 | $18.19M derived: sum of 2 quarters · filed 2019-11-13 | $15.21M derived: sum of 3 quarters · filed 2019-11-13 | $11.99M derived: sum of 4 quarters · filed 2019-11-13 | ||||
| 2018-06-30 | $20.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-09 | $17.24M derived: sum of 2 quarters · filed 2019-09-09 | $14.02M derived: sum of 3 quarters · filed 2019-09-09 | $11.31M 10-K · filed 2019-09-09 | ||||
| 2018-03-31 | -$2.98M 10-Q · filed 2019-05-14 | -$6.20M derived: sum of 2 quarters · filed 2019-05-14 | -$8.90M 10-Q · filed 2019-05-14 | -$11.62M derived: sum of 4 quarters · filed 2019-06-03 | ||||
| 2017-12-31 | -$3.22M 10-Q · filed 2019-02-11 | -$5.92M 10-Q · filed 2019-02-11 | -$8.64M derived: sum of 3 quarters · filed 2019-06-03 | -$10.72M derived: sum of 4 quarters · filed 2019-06-03 | ||||
| 2017-09-30 | -$2.71M 10-Q · filed 2018-11-13 | $2.71M 10-Q · filed 2017-11-09 | -$5.42M derived: sum of 2 quarters · filed 2019-06-03 | -$7.50M derived: sum of 3 quarters · filed 2019-06-03 | -$8.98M derived: sum of 4 quarters · filed 2019-06-03 | |||
| 2017-06-30 | -$2.71M derived: 8-K 12 month − 10-Q 9 month · filed 2019-06-03 | -$4.79M derived: sum of 2 quarters · filed 2019-06-03 | -$6.27M derived: sum of 3 quarters · filed 2019-06-03 | -$8.87M 8-K · filed 2019-06-03 | $8.87M 10-K · filed 2017-09-27 | |||
| 2017-03-31 | -$2.08M 10-Q · filed 2018-05-15 | $2.08M 10-Q · filed 2017-05-12 | -$3.56M derived: sum of 2 quarters · filed 2018-05-15 | -$6.16M 10-Q · filed 2018-05-15 | $6.16M 10-Q · filed 2017-05-12 | $2.73M derived: sum of 4 quarters · filed 2018-05-15 | ||
| 2016-12-31 | -$1.48M 10-Q · filed 2018-02-14 | $1.48M 10-Q · filed 2017-02-10 | -$4.08M 10-Q · filed 2018-02-14 | $4.08M 10-Q · filed 2017-02-10 | $4.81M derived: sum of 3 quarters · filed 2018-02-14 | $5.95M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-09-30 | $2.60M 10-Q · filed 2017-11-09 | -$2.60M 10-Q · filed 2016-11-10 | $6.29M derived: sum of 2 quarters · filed 2017-11-09 | $7.43M derived: sum of 3 quarters · filed 2017-11-09 | $10.08M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-27 | $4.84M derived: sum of 2 quarters · filed 2017-09-27 | $7.48M derived: sum of 3 quarters · filed 2017-09-27 | $9.10M 10-K · filed 2017-09-27 | ||||
| 2016-03-31 | $1.14M 10-Q · filed 2017-05-12 | $3.79M derived: sum of 2 quarters · filed 2017-05-12 | $5.41M 10-Q · filed 2017-05-12 | |||||
| 2015-12-31 | $2.65M 10-Q · filed 2017-02-10 | $4.27M 10-Q · filed 2017-02-10 | ||||||
| 2015-09-30 | -$1.62M 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |